Mazdutide

Metabolic

aka IBI362 · LY3305677 · Oxyntomodulin analogue

Compare

Formula

—

MW (Da)

Half-life

~7 days

Saves

0

Overview

Mazdutide (IBI362, LY3305677) is a once-weekly synthetic oxyntomodulin analogue with a fatty-acyl moiety for extended exposure. It is a dual GLP-1R / GCGR agonist. Innovent has reported NMPA approval in China for chronic weight management and later for glycemic control in adults with type 2 diabetes; outside China it remains investigational.

Mechanism

Preclinical work describes mazdutide as a balanced GLP-1R/GCGR dual agonist that potently binds both human and mouse versions of each receptor. The intended biology is class-standard: GLP-1R agonism delivers appetite suppression, delayed gastric emptying, and glucose lowering, while GCGR agonism contributes higher energy expenditure and fat oxidation. Exact numerical affinity constants were not specified in the accessible primary abstracts, so the mechanism is best described qualitatively as a balanced oxyntomodulin-style dual agonist.

Vendors

—

no vendors yet

Lowest price

—

Reported benefits

Phase 3 weight loss in Chinese adults with obesity

In a phase 3 obesity trial in Chinese adults, once-weekly mazdutide at 4 mg and 6 mg produced clinically meaningful weight loss over 32 weeks.

[mazdu-nejm-phase3]

clinical

A1C and weight reduction in type 2 diabetes

In a placebo-controlled phase 3 type 2 diabetes study, HbA1c fell 1.57% with 4 mg and 2.15% with 6 mg at week 24, while body weight fell 5.61% and 7.81% respectively.

[mazdu-nejm-phase3]

clinical

Reported NMPA approval in China

Innovent reported NMPA approval for chronic weight management and subsequently for type 2 diabetes, making mazdutide the first dual GCG/GLP-1 receptor agonist to reach a national regulatory approval.

[mazdu-nmpa-press]

clinical

Reported side effects

GI side effects dominant (diarrhea, decreased appetite, nausea, vomiting)
clinical
Tolerability is dominated by GI events. In a phase 3 T2D study the most common adverse events were diarrhea (36%), decreased appetite (29%), nausea (23%), and vomiting (14%). The phase 3 obesity report described these events as mostly mild to moderate, especially during dose escalation.
English-language labeling and long-term outcomes still limited
anecdotal
Most published clinical data come from Chinese populations and indication settings, and an accessible English-language package insert with full storage and titration details was not located in the reviewed sources.

Dosing notes

Approved-in-China use is once-weekly subcutaneous. Main approved or near-approved weekly maintenance doses are 4 mg and 6 mg, with earlier obesity work going up to 6 mg via dose escalation and later obesity studies examining 9 mg and 10 mg. Detailed English-language approved titration instructions were not recoverable from the reviewed sources.

Research use only. Information on this page is editorial reference, not medical or dosing advice. Always consult qualified medical guidance before use.

Storage

Unspecified in the reviewed official English-language sources. An accessible English package insert with authoritative storage conditions was not located; defer to the brand-specific Chinese label for current storage guidance.

Vendors carrying Mazdutide

No approved vendors are listing this peptide yet. Check back later or browse the full vendor directory.

Discussion

Ask, answer, and vote on questions about Mazdutide.

No questions yet. Be the first to ask.

References

[mazdu-nejm-phase3]
Once-Weekly Mazdutide in Chinese Adults with Obesity / Type 2 Diabetes
Authors per NEJM entry · New England Journal of Medicine
Source
[mazdu-nature]
Mazdutide preclinical characterization (GLP-1R/GCGR dual agonist)
Authors per Nature Communications entry · Nature Communications
Source
[mazdu-nmpa-press]
Innovent announces mazdutide NMPA approval for chronic weight management
Innovent Biologics · PR Newswire / Innovent
Source

Reported benefits

Phase 3 weight loss in Chinese adults with obesity

A1C and weight reduction in type 2 diabetes

Reported NMPA approval in China

GI side effects dominant (diarrhea, decreased appetite, nausea, vomiting)

English-language labeling and long-term outcomes still limited

Discussion